Compare INCR & IBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INCR | IBIO |
|---|---|---|
| Founded | 1994 | 2008 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.6M | 52.8M |
| IPO Year | 2021 | 2009 |
| Metric | INCR | IBIO |
|---|---|---|
| Price | $3.39 | $0.74 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $5.69 |
| AVG Volume (30 Days) | 4.6K | ★ 646.8K |
| Earning Date | 11-17-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 81.71 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $208.74 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.68 | $0.69 |
| 52 Week High | $6.10 | $3.82 |
| Indicator | INCR | IBIO |
|---|---|---|
| Relative Strength Index (RSI) | 23.91 | 37.87 |
| Support Level | $0.81 | $0.71 |
| Resistance Level | $5.58 | $1.52 |
| Average True Range (ATR) | 0.24 | 0.07 |
| MACD | -0.13 | 0.02 |
| Stochastic Oscillator | 9.15 | 33.63 |
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. Its products are available in dried inflorescences or liquid oil form, and are marketed through various brands, including Pharmo Cann, Humboldt, Indoor, Space Labs, Canndoc Utopia, Binske, Canndoc Stars, and others. The company has two operating segments, namely Investments in portfolio companies in the biomed sector and Investments in the medical cannabis sector. A majority of its revenue is generated from the Cannabis segment.
iBio Inc is a clinical-stage biotechnology company using Artificial Intelligence (AI) for the development of hard-to-drug precision antibodies for obesity, cardiometabolic, and cardiopulmonary diseases. Its product candidate pipeline includes IBIO-610, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody program targeting myostatin, growth differentiation factor 11 (GDF11), and Activin A; IBIO-600; Amylin Antibody; and Target 4, in different stages of development, being developed as potential therapies for obesity and cardiometabolic disease. The company operates as one reportable segment, which is that of a biotechnology company leveraging AI and ML for the development of hard-to-drug precision antibodies.